Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) are the liver manifestations of a range of metabolic conditions including obesity, type 2 diabetes (T2D), insulin resistance, hypertension and dyslipidemia.
Professors Aleksander Krag (hepatologist from the University of Southern Denmark, Odense University Hospital) and Geltrude Mingrone (endocrinologist from King’s College London and Università Cattolica del S. Cuore) discuss the role of endocrinologists and the importance of multidisciplinary collaboration for the management of patients with MASLD or MASH, particularly focusing on how to assess liver health in patients with T2D.
The endocrinologist and the patient with MASLD/MASH
Learning Objectives
To raise awareness of MASLD/MASH as a manifestation of metabolic disease
To improve understanding of risk factors and comorbidities for MASLD/MASH, focusing on type 2 diabetes
To highlight the role of endocrinology in the diagnosis and management of people with MASLD/MASH, in light of potential metabolic comorbidities such as obesity and type 2 diabetes
To discuss optimal multidisciplinary collaboration between endocrinology, primary care and hepatology to improve care of people with MASLD/MASH
The following speakers have received an honorarium from Novo Nordisk for their input to and facilitation of this educational material:
- Prof. Aleksander Krag, University of Southern Denmark, Odense University Hospital, Denmark
- Prof. Geltrude Mingrone, King’s College London, UK, and Università Cattolica del S. Cuore, Italy
References
1. Kasper P, et al. Clin Res Cardiol. 2021;110:921–937
2. Muzurović E, et al. Hypertension. 2022;79:1319–1326
